Pressmeddelande

Cline Scientific receives Decision to Grant for StemCART in Europe

Cision Publicerad: 23 May 2023 14:50

Cline Scientific has received a Decision to Grant from the European Patent Office (EPO) related to the StemCART patent.

The patent application is titled "A method for providing a cartilage implant with chondrocytes". The decision will take effect from the 14th of June 2023.

The notice of allowance for this patent was received from EPO and a press release was sent out in April.

More about StemCART

StemCART is a preclinical Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide.

For more information, please contact:

Hanne Evenbratt, Interim CEO and VP – Research & Development

Email: [email protected]

Phone: +46 704 88 79 23

Bifogade filer

Releasehttps://mb.cision.com/Main/12114/3773411/2076871.pdf

Nyheter om Cline Scientific

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!